OBJECTIVE: To determine the fatal and non-fatal cardiovascular event rate in patients with intermittent claudication treated with antiplatelet agents. METHODS AND DESIGN: Patients with PAD-II stage Fontaine (n=223) and sex and age matched controls (n=446) were followed up from 1974 to 1998. All patients were treated with antiplatelet agents (aspirin, 325 mg once daily or ticlopidine, 250 mg twice daily) and for risk factors, if present. The end points were death for any cause (vascular event, cancer, and others) and non-fatal vascular events (myocardial infarction, ischemic/hemorrhagic stroke, and leg amputation). RESULTS: PAD patients had a significantly higher mortality rate than controls (3.99 vs. 2.53 deaths for 100 patients per year, respectively), cancer (mostly lung, stomach and colon) and vascular mortality accounted for such difference. The incidence of non-fatal vascular events was three times higher in patients than in controls (1.7 vs. 0.56, 100 patients per year, respectively, p<0.05) even considering amputation separately (0.28 vs. 0.00, 100 patients per year, p<0.05). No difference between patients treated with aspirin or ticlopidine could be found in both end points. CONCLUSIONS: Vascular mortality and morbidity, despite the use of antiplatelet agents, are still higher than sex and age matched controls; however, the commonest cause of death is cancer.
OBJECTIVE: To determine the fatal and non-fatal cardiovascular event rate in patients with intermittent claudication treated with antiplatelet agents. METHODS AND DESIGN:Patients with PAD-II stage Fontaine (n=223) and sex and age matched controls (n=446) were followed up from 1974 to 1998. All patients were treated with antiplatelet agents (aspirin, 325 mg once daily or ticlopidine, 250 mg twice daily) and for risk factors, if present. The end points were death for any cause (vascular event, cancer, and others) and non-fatal vascular events (myocardial infarction, ischemic/hemorrhagic stroke, and leg amputation). RESULTS: PAD patients had a significantly higher mortality rate than controls (3.99 vs. 2.53 deaths for 100 patients per year, respectively), cancer (mostly lung, stomach and colon) and vascular mortality accounted for such difference. The incidence of non-fatal vascular events was three times higher in patients than in controls (1.7 vs. 0.56, 100 patients per year, respectively, p<0.05) even considering amputation separately (0.28 vs. 0.00, 100 patients per year, p<0.05). No difference between patients treated with aspirin or ticlopidine could be found in both end points. CONCLUSIONS: Vascular mortality and morbidity, despite the use of antiplatelet agents, are still higher than sex and age matched controls; however, the commonest cause of death is cancer.
Authors: Alexander M de Vos; Annemarieke Rutten; Hester J van de Zaag-Loonen; Michiel L Bots; Riksta Dikkers; Robert A Buiskool; Willem P Mali; Daniel D Lubbers; Arend Mosterd; Mathias Prokop; Benno J Rensing; Maarten J Cramer; H Wouter van Es; Frans L Moll; Eric D van de Pavoordt; Pieter A Doevendans; Birgitta K Velthuis; Albert J Mackaay; Felix Zijlstra; Matthijs Oudkerk Journal: Trials Date: 2008-08-01 Impact factor: 2.279
Authors: Barbara Rantner; Barbara Kollerits; Johannes Pohlhammer; Marietta Stadler; Claudia Lamina; Slobodan Peric; Peter Klein-Weigel; Hannes Mühlthaler; Gustav Fraedrich; Florian Kronenberg Journal: Sci Rep Date: 2017-04-03 Impact factor: 4.379
Authors: Marco De Carlo; Giovanni Di Minno; Tobias Sayre; Mir Sohail Fazeli; Gaye Siliman; Claudio Cimminiello Journal: Curr Vasc Pharmacol Date: 2021 Impact factor: 2.719